EVKEEZA
Procedural steps taken and scientific information after the authorisation
Application 
Scope
number
Opinion/ 
Commission 
Product 
Summary
Notification1 
Decision 
Information 
issued on
Issued2 / 
affected3 
amended 
on
II/0011
Extension of indication to include the treatment of 
09/11/2023
11/12/2023
SmPC, Annex 
Please refer to Scientific Discussion ‘EMEA-H-C-005449-II-
paediatric patients with homozygous familial 
hypercholesterolaemia (HoFH) aged 5 years and 
older for EVKEEZA, based on interim results from 
study R1500-CL-17100, as well as supportive 
information from an updated interim analysis of 
study R1500-CL-1719, and an extrapolation analysis 
(including population PK, population PK/PD, and 
II and PL
0011’
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures.
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us 
Send us a question  Go to www.ema.europa.eu/contact  Telephone +31 (0)88 781 6000
An agency of the European Union
simulation analyses). R1500-CL-17100 is an ongoing 
multicentre, three-part, single-arm, open-label study 
evaluating the efficacy, safety, and tolerability of 
evinacumab in paediatric patients aged ≥ 5 to 11 
years with HoFH. As a consequence, sections 4.1, 
4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The 
Annex II and the Package Leaflet are updated in 
accordance. Version 1.2 of the RMP has also been 
submitted. In addition, the marketing authorisation 
holder took the opportunity to introduce minor 
editorial changes to the PI. Furthermore, the PI is 
brought in line with the latest QRD template version 
10.3.
C.I.6.a - Change(s) to therapeutic indication(s) - 
Addition of a new therapeutic indication or 
modification of an approved one
IB/0014
B.I.a.2.a - Changes in the manufacturing process of 
30/11/2023
n/a
the AS - Minor change in the manufacturing process 
of the AS
IB/0012/G
This was an application for a group of variations.
09/11/2023
n/a
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process
B.II.b.5.a - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Tightening of in-process limits
Page 2/5
PSUSA/10945
Periodic Safety Update EU Single assessment - 
28/09/2023
n/a
PRAC Recommendation - maintenance
/202302
evinacumab
S/0010
Annual re-assessment.
14/09/2023
IB/0009
B.II.h.1.b.2 - Update to the Adventitious Agents 
15/06/2023
n/a
n/a
Safety Evaluation information - Replacement of 
obsolete studies related to manufacturing steps and 
adventitious agents already reported in the dossier - 
without modifications of risk assessment
PSUSA/10945
Periodic Safety Update EU Single assessment - 
16/03/2023
n/a
PRAC Recommendation - maintenance
/202208
evinacumab
IAIN/0006/G
This was an application for a group of variations.
12/10/2022
05/10/2023
SmPC, Annex 
II and PL
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site
B.II.b.5.c - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Deletion of a non-significant in-process test
A.6 - Administrative change - Change in ATC 
Code/ATC Vet Code
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Page 3/5
Not including batch control/testing
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing
PSUSA/10945
Periodic Safety Update EU Single assessment - 
29/09/2022
n/a
PRAC Recommendation - maintenance
/202202
evinacumab
S/0005
1st annual re-assessment
15/09/2022
n/a
The CHMP, having reviewed the evidence of compliance 
with the specific obligations and the impact of the data 
submitted by the MAH on the benefit/risk profile of the 
medicinal product, concluded that marketing authorisation 
of EVKEEZA should be maintained.
T/0003
Transfer of Marketing Authorisation
31/03/2022
13/04/2022
SmPC, 
Labelling and 
PL
IB/0002/G
This was an application for a group of variations.
11/04/2022
n/a
B.II.f.1.e - Stability of FP - Change to an approved 
stability protocol
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data
B.II.d.1.a - Change in the specification parameters 
and/or limits of the finished product - Tightening of 
specification limits
B.I.b.1.b - Change in the specification parameters 
Page 4/5
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits
PSUSA/10945
Periodic Safety Update EU Single assessment - 
10/03/2022
n/a
PRAC Recommendation - maintenance
/202108
evinacumab
Page 5/5
